Alfred E. Slanetz
Fondateur chez Geneius Biotechnology, Inc.
Profil
Alfred E.
Slanetz is the founder of Geneius Biotechnology, Inc. founded in 2014, where he holds the titles of President, Chief Executive Officer & Director.
He is currently a Director at Aim-Hi Accelerator Fund, Inc. Dr. Slanetz's former positions include President & Chief Executive Officer at bluebird bio, Inc., Head-New Product Planning at Genentech, Inc., and Vice President-Business Development at Transgene SA. Dr. Slanetz's education includes a graduate degree from Brown University, an undergraduate degree from Hamilton College (New York), and a doctorate degree from Yale University.
Postes actifs de Alfred E. Slanetz
Sociétés | Poste | Début |
---|---|---|
Geneius Biotechnology, Inc.
Geneius Biotechnology, Inc. Miscellaneous Commercial ServicesCommercial Services Geneius Biotechnology, Inc. operates as an immuno-oncology company. It develops autologous, adoptive T cell therapy technology which generates robust immune response to cancer. The company was founded by Alfred E. Slanetz in 2015 and is headquartered in Natick, MA. | Fondateur | 01/01/2015 |
Aim-Hi Accelerator Fund, Inc.
Aim-Hi Accelerator Fund, Inc. Miscellaneous Commercial ServicesCommercial Services Aim-Hi Accelerator Fund, Inc. is a non-profit company that was born out of the National Foundation for Cancer Research (NFCR). The company is based in Rockville, MD. The company aims to bridge the gap between innovative, early-stage cancer research and successful development of high-impact oncology products. Aim-Hi is a new paradigm to fund translational research designed to focus on startups that have commercial potential at cancer therapeutic discovery. The company was founded by Sujuan Ba, Charlie Weatherspoon, Franklin Cary Salisbury. Sujuan Ba has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
Anciens postes connus de Alfred E. Slanetz
Sociétés | Poste | Fin |
---|---|---|
TRANSGENE | Corporate Officer/Principal | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
BLUEBIRD BIO, INC. | President | - |
Formation de Alfred E. Slanetz
Yale University | Doctorate Degree |
Brown University | Graduate Degree |
Hamilton College (New York) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
TRANSGENE | Health Technology |
Entreprise privées | 3 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Geneius Biotechnology, Inc.
Geneius Biotechnology, Inc. Miscellaneous Commercial ServicesCommercial Services Geneius Biotechnology, Inc. operates as an immuno-oncology company. It develops autologous, adoptive T cell therapy technology which generates robust immune response to cancer. The company was founded by Alfred E. Slanetz in 2015 and is headquartered in Natick, MA. | Commercial Services |
Aim-Hi Accelerator Fund, Inc.
Aim-Hi Accelerator Fund, Inc. Miscellaneous Commercial ServicesCommercial Services Aim-Hi Accelerator Fund, Inc. is a non-profit company that was born out of the National Foundation for Cancer Research (NFCR). The company is based in Rockville, MD. The company aims to bridge the gap between innovative, early-stage cancer research and successful development of high-impact oncology products. Aim-Hi is a new paradigm to fund translational research designed to focus on startups that have commercial potential at cancer therapeutic discovery. The company was founded by Sujuan Ba, Charlie Weatherspoon, Franklin Cary Salisbury. Sujuan Ba has been the CEO since incorporation. | Commercial Services |